CJC-1295 with DAC

Long-Acting Growth Hormone-Releasing Peptide: CJC-1295 with DAC

CJC-1295 with DAC (Drug Affinity Complex) is a synthetically engineered peptide construct based upon naturally occurring growth hormone–releasing hormone (GHRH). The compound was strategically designed to overcome the inherent biochemical instability of native GHRH through incorporation of a specialized albumin-binding domain that dramatically improves chemical stability and extends the therapeutic timeframe. The DAC technology allows the peptide to associate with abundant serum albumin, which effectively blocks kidney-mediated clearance and limits enzymatic hydrolysis. The end result is dramatically prolonged stimulation of GH secretion that substantially exceeds the short activity window observed with standard GHRH preparations.

Mechanism of Action and Physiological Significance

CJC-1295 engineered with a Drug Affinity Complex modification constitutes a long-acting GHRH receptor agonist specifically designed to maximize chemical stability and extend the period of GH-stimulating activity. The peptide exerts its action by engaging GHRH receptors on pituitary somatotroph cells, triggering intracellular signaling mechanisms that elicit rhythmic pulsatile GH secretion consistent with physiologic endogenous patterns.

Once secreted into the circulatory system, GH functions as an endocrine hormone stimulating hepatic and tissue synthesis of insulin-like growth factor-1 (IGF-1), which acts as the primary effector mediating growth promotion, tissue remodeling, and cell division. The combined physiological actions of GH and IGF-1 constitute the master regulatory system controlling energy metabolism, mobilization of adipose tissue energy stores, and deposition of structural muscle proteins. Particularly important, GH promotes lipid mobilization across all anatomical adipose compartments while concurrently preserving skeletal muscle structural and functional capacity.

The principal advantage conferred by the DAC technology involves the ability of the modified peptide to establish and maintain stable associations with serum albumin present in blood. This interaction dramatically prolongs the peptide's circulation time, enabling continuous receptor occupation and sustained GH secretory output. As a result, CJC-1295 with DAC demonstrates biological activity persisting for multiple days to weeks post-injection—substantially exceeding the brief functional window of non-DAC peptides including standard CJC-1295 or unmodified GHRH(1-29).

From a subcellular perspective, CJC-1295 binding to GHRH receptors presumably triggers adenylate cyclase activity, leading to the synthesis of cyclic adenosine monophosphate (cAMP). This intracellular messenger activates protein kinase A (PKA), which phosphorylates regulatory transcription factor proteins and increases transcription of GH-encoding genes in pituitary somatotrophs. The extended presence of the albumin-associated peptide maintains continuous activation of this signaling sequence, producing cumulative increases in GH secretion and amplified IGF-1 production exceeding that of rapidly-degraded peptide compounds.

Overall, CJC-1295 with DAC functions as an exceptionally useful research model for investigating prolonged endocrine activation mechanisms, characterizing the regulatory architecture of the GH/IGF-1 system, and assessing the metabolic and physiological outcomes of extended pulsatile GH secretion.

CJC-1295 with DAC: Molecular Properties and Composition

Chemical and Structural Profile

Appearance: Off-white powder in lyophilized form

Molecular Formula: C₁₆₅H₂₇₁N₄₇O₄₆

Molecular Weight: Approximately 3647.9 g/mol

Sequence Structure: DAC-modified GHRH(1–29) derivative

Purity Level: ≥ 98% according to analytical documentation

CJC-1295 with DAC: Research Applications and Laboratory Protocols

Storage Specifications and Environmental Conditions

CJC-1295 with DAC is supplied as a sterile, lyophilized peptide preparation intended for laboratory research purposes. For optimal maintenance of chemical structure and biological activity, the powder form should be stored at –20°C. Upon dissolution into solution, the peptide preparation must be manipulated using aseptic sterile procedures and stored at 2–8°C when immediate experimental application is planned. Adherence to these environmental specifications protects the molecular structure from unwanted chemical transformation and minimizes the likelihood of contaminating microorganisms compromising experimental validity.

GH Secretion Elevation and Temporal Profile

Both human clinical investigations and animal research models have shown that a single injection of CJC-1295 with DAC produces marked elevation in GH and IGF-1 that remains evident for approximately one week. This extended hormonal response contrasts markedly with the brief secretory response induced by native GHRH(1-29) or non-DAC peptide variants. Quantitative analyses show IGF-1 levels approximately 2–3-fold above baseline paired with stable pulsatile GH secretion patterns, demonstrating robust receptor-mediated activation and sustained peptide availability in the bloodstream.

Metabolic Modifications and Systemic Effects

Experimental data suggest CJC-1295 with DAC produces marked alterations in metabolic state through elevation of circulating GH and IGF-1 levels. Preclinical research findings document increased rates of adipose tissue lipolysis, enhanced oxidative breakdown of fatty acids, and preservation of lean muscle tissue—all effects consistent with GH's recognized anabolic and catabolic metabolic roles. Investigation has examined the compound's effects on amino acid polymerization into structural proteins, acceleration of tissue regeneration, and modification of whole-body energy utilization, supporting its use as a research platform for investigating metabolic pathways controlled by growth hormone.

Pharmacokinetic Characteristics and Prolonged Activity Duration

Unlike rapid-acting GHRH compounds, CJC-1295's DAC modification permits formation of stable peptide-albumin complexes, markedly reducing renal clearance and enzymatic inactivation. The strong association between the peptide and serum albumin substantially extends the duration of biochemically active compound remaining in circulation, perpetuating continuous receptor signaling and protracted endocrine stimulation. Pharmacokinetic calculations indicate a terminal elimination half-life of approximately 5.8 to 8.1 days, substantially prolonging blood residence relative to the minutes-to-hours clearance pattern of non-albumin-binding peptides, thereby permitting reduced dosing intervals in research applications.

Scientific Compilation and Expert Recognition

Literature Review and Scholarly Curation

This comprehensive scientific literature review was carefully compiled, systematically evaluated, and logically arranged by Dr. Stuart L. Teichman, M.D. A prominent authority in endocrinology and clinical research methodology, Dr. Teichman has conducted transformative investigations into extended-acting GHRH-based compounds with specific focus on CJC-1295. His pioneering studies have characterized the pharmacological features, safety portfolio, and clinical applicability of GHRH peptide therapeutics, revealing their remarkable capacity to produce sustained elevations in GH and IGF-1. Dr. Teichman's scientific accomplishments have profoundly influenced the field of peptide endocrinology and the development of extended-duration hormonal pharmaceutical agents.

Research Contributions and Collaborative Investigations

Dr. Stuart L. Teichman has dedicated his professional research efforts to examining GH-stimulating peptide compounds, GHRH-derived analogs, and peptide-based mechanisms of endocrine regulation. In partnership with distinguished co-investigators A. Neale, B. Lawrence, and C. Gagnon, Dr. Teichman has generated comprehensive peer-reviewed scientific publications examining the molecular foundations of extended-duration GHRH compounds, their influence on GH/IGF-1 regulatory systems, and their effects on metabolic homeostasis. His cumulative scientific work constitutes a foundational knowledge base supporting the development of modern peptide-based pharmaceutical therapeutics targeting hormonal stability and metabolic health improvement.

This acknowledgment is provided exclusively for the purpose of scientific attribution and should not be understood as an endorsement statement, marketing communication, or expression of organizational affiliation. Montreal Peptides Canada confirms no partnership arrangement, sponsorship agreement, or professional relationship with Dr. Teichman or any of the referenced scientific collaborators.

Scientific Literature and References

Teichman SL, Neale A, Lawrence B, Gagnon C, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/

Broglio F, et al. Growth hormone secretagogues: clinical perspectives and safety concerns. Growth Horm IGF Res. 2009;19(1):1-9. https://pubmed.ncbi.nlm.nih.gov/19054601/

Ghigo E, et al. Growth hormone secretagogues: physiology and clinical applications. Endocr Rev. 2005;26(3):345-376. https://pubmed.ncbi.nlm.nih.gov/15814849/

Anderson-Baucum EK, et al. GH/IGF-1 axis and metabolic regulation. Mol Cell Endocrinol. 2018;469:1-14. https://pubmed.ncbi.nlm.nih.gov/29288913/

Wu Z, et al. Growth hormone and IGF-1 signaling in muscle metabolism. Front Endocrinol (Lausanne). 2020;11:607. https://pubmed.ncbi.nlm.nih.gov/33281526/

Ranke MB, Wit JM. Growth hormone-past, present and future. Nat Rev Endocrinol. 2018;14(5):285-300. https://pubmed.ncbi.nlm.nih.gov/29479014/

Strasburger CJ, et al. GH and IGF-1 in clinical practice: new insights## Version 1

CJC-1295 with DAC: A Long-Acting Growth Hormone Releasing Hormone Analog

CJC-1295 with DAC (Drug Affinity Complex) represents a laboratory-engineered peptide derived from growth hormone–releasing hormone (GHRH). This compound has been structurally modified to improve its resistance to degradation and extend its period of biological availability. The DAC component allows the molecule to attach to albumin proteins circulating in blood plasma, which substantially decreases the rate at which enzymes and kidneys eliminate the compound. The consequence is sustained activation of growth hormone secretion that surpasses the activity profile of unmodified GHRH molecules, creating a more consistent hormonal stimulus over time.

Overview of CJC-1295 with DAC Mechanism

CJC-1295 featuring a Drug Affinity Complex modification is classified as an extended-duration version of GHRH designed to maximize both chemical stability and the timeframe during which growth hormone (GH) stimulation occurs. The peptide functions by engaging pituitary GHRH receptors, setting off biochemical pathways within cells that trigger the rhythmic secretion of GH, which closely resembles the body's natural hormone pulsing patterns.

Following its release from the pituitary, GH prompts liver and other tissues to generate insulin-like growth factor-1 (IGF-1), which orchestrates anabolic responses, accelerates tissue reconstruction, and stimulates cell division. The combined action of GH alongside IGF-1 fundamentally influences energy balance, fat mobilization, and muscle protein development. GH specifically participates in the breakdown of lipids across deep and surface fat deposits while simultaneously preserving muscular tissue mass.

The DAC portion of CJC-1295 offers a significant therapeutic advantage through its capacity to establish a lasting chemical connection with circulating blood proteins (serum albumin). This association dramatically lengthens how long the compound persists in the bloodstream, supporting prolonged interaction with GH receptors and continuous GH discharge. Consequently, CJC-1295 with DAC sustains its function across multiple days or weeks post-injection—substantially outperforming rapidly-degraded versions such as standard CJC-1295 or basic GHRH(1-29).

From a biochemical perspective, CJC-1295 engagement with the GHRH receptor is thought to activate the cAMP pathway via stimulation of an enzyme called adenylate cyclase. This sequential process then activates protein kinase A (PKA), which phosphorylates key regulatory proteins that boost expression of GH-encoding genes in pituitary GH-producing cells. The prolonged presence of the DAC-modified peptide maintains this cascade, resulting in higher total GH release and amplified IGF-1 production relative to fast-clearing alternatives.

In summary, CJC-1295 with DAC functions as an effective experimental platform for investigating sustained hormonal activation, how the GH/IGF-1 system operates, and metabolic consequences resulting from prolonged and consistent GH pulsatile secretion.

CJC-1295 with DAC: Molecular Composition

Chemical Specifications

Appearance: Colorless powdered form following freeze-drying procedures

Molecular Formula: C₁₆₅H₂₇₁N₄₇O₄₆

Molecular Weight: Approximately 3647.9 daltons

Sequence: GHRH(1–29) framework bearing DAC modification

Purity Analysis: ≥ 98% per Certificate of Analysis

CJC-1295 with DAC: Laboratory Investigation Methods

Storage Requirements and Preservation

CJC-1295 with DAC comes supplied as a purified, freeze-dried powder preparation. To preserve its chemical structure and functional properties throughout storage, maintaining a temperature of –20°C in the anhydrous state is strongly advised. After dissolving the powder, the resulting solution must be handled under sterile conditions and retained at temperatures between 2–8°C if immediate use is anticipated. This approach guarantees the chemical integrity of the substance and decreases the likelihood of unwanted chemical transformation or introduction of foreign matter during research operations.

CJC-1295 with DAC Effects on Growth Hormone Output

Human trials and animal model research have shown that one dose of CJC-1295 with DAC produces prolonged increases in blood concentrations of GH and IGF-1 persisting approximately seven days. This extended hormonal response demonstrates a clear contrast to the transient effects of conventional GHRH(1-29) or earlier peptide variations. Research findings indicate IGF-1 climbs 2–3 times above baseline, accompanied by rhythmic patterns of GH secretion, pointing to robust receptor signaling and extended pharmacological persistence within circulation.

CJC-1295 with DAC and Physiological Metabolism

Scientific investigations indicate CJC-1295 with DAC generates considerable effects on body metabolism, primarily through raising circulating levels of GH and IGF-1. Laboratory research shows outcomes including accelerated fat breakdown, superior capacity for fat utilization, and preservation of skeletal muscle, all fitting with GH's recognized capacity to both break down and build tissue. The compound has been assessed regarding impacts on amino acid assembly into proteins, acceleration of wound healing, and shifts in caloric expenditure, presenting an important model for studying how GH regulates metabolic operations.

CJC-1295 with DAC and Extended Bioavailability

Unlike its shorter-duration counterparts, the DAC technology in CJC-1295 permits binding to albumin in blood, dramatically lowering how rapidly kidneys remove it and decreasing susceptibility to enzymatic destruction. The peptide's attachment to albumin substantially prolongs its residence time in plasma, maintaining biological function and continuous stimulation of the endocrine system. Mathematical modeling of drug elimination indicates the substance maintains half its concentration for roughly 5.8 to 8.1 days, substantially exceeding the minutes-to-hours timeframe of its non-DAC variants, thereby reducing the frequency of doses needed during studies.

Attribution and Scientific Leadership

Authorial Contribution

This compilation of scientific literature was assembled, reviewed, and structured by Dr. Stuart L. Teichman, M.D. A prominent expert in endocrinology and experimental medicine, Dr. Teichman has pioneered investigations into extended-duration GHRH analogs, with particular emphasis on CJC-1295. His seminal publications characterized the pharmacology, tolerability profile, and possible therapeutic applications of GHRH-based compounds, illustrating their power to sustain GH and IGF-1 elevation. Dr. Teichman's investigations have substantially advanced peptide endocrinology and the design of hormone preparations with prolonged effects.

Peer-Reviewed Journal Contributions

Throughout his professional career, Dr. Stuart L. Teichman has concentrated on investigating GH secretion agents, GHRH peptide derivatives, and hormone modulation via synthetic peptides. In partnership with colleagues including A. Neale, B. Lawrence, and C. Gagnon, Dr. Teichman has extensively published research regarding the biological pathways governing extended-duration GHRH compounds, regulatory mechanisms within the GH/IGF-1 circuit, and systemic metabolic outcomes. His accumulated scientific output constitutes a pivotal reference for advancement of modern peptide-based pharmaceutical treatments focused on hormonal equilibrium and metabolic wellness.

This reference to Dr. Teichman's contributions is provided solely for scientific attribution and does not represent endorsement or marketing language. Montreal Peptides Canada holds no organizational partnership, endorsement agreement, or collegial relationship with Dr. Teichman or the named scientific collaborators.

Scientific References

Teichman SL, Neale A, Lawrence B, Gagnon C, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/

Broglio F, et al. Growth hormone secretagogues: clinical perspectives and safety concerns. Growth Horm IGF Res. 2009;19(1):1-9. https://pubmed.ncbi.nlm.nih.gov/19054601/

Ghigo E, et al. Growth hormone secretagogues: physiology and clinical applications. Endocr Rev. 2005;26(3):345-376. https://pubmed.ncbi.nlm.nih.gov/15814849/

Anderson-Baucum EK, et al. GH/IGF-1 axis and metabolic regulation. Mol Cell Endocrinol. 2018;469:1-14. https://pubmed.ncbi.nlm.nih.gov/29288913/

Wu Z, et al. Growth hormone and IGF-1 signaling in muscle metabolism. Front Endocrinol (Lausanne). 2020;11:607. https://pubmed.ncbi.nlm.nih.gov/33281526/

Ranke MB, Wit JM. Growth hormone-past, present and future. Nat Rev Endocrinol. 2018;14(5):285-300. https://pubmed.ncbi.nlm.nih.gov/29479014/

Strasburger CJ, et al. GH and IGF-1 in clinical practice: new insights. Eur J Endocrinol. 2021;185(6):R123-R136. https://pubmed.ncbi.nlm.nih.gov/34870144/

Smith TR, et al. The role of GH and IGF-1 in tissue repair and regeneration. Exp Gerontol. 2015;68:46-52. https://pubmed.ncbi.nlm.nih.gov/25987250/

Version 2

CJC-1295 with DAC Peptide: Scientific Overview

CJC-1295 containing the DAC (Drug Affinity Complex) modification is a laboratory-synthesized variant of the natural growth hormone–releasing hormone (GHRH). Through strategic chemical engineering, this compound achieves superior resistance to breakdown and extends the window of therapeutic activity. The incorporation of DAC facilitates interaction with serum albumin proteins within circulation, thereby minimizing the removal rate mediated by renal filtration and proteolytic enzymes. This results in sustained, consistent stimulation of GH secretion that exceeds the brief responsiveness characteristic of native GHRH, ensuring prolonged endocrine engagement.

Comprehensive Technical Overview

CJC-1295 equipped with a Drug Affinity Complex represents a modified iteration of GHRH engineered specifically to enhance molecular durability and amplify the duration of GH-stimulatory effects. Upon administration, the compound binds to GHRH receptors present on pituitary cells, triggering intracellular messaging mechanisms that prompt the cyclical discharge of GH, faithfully replicating the body's intrinsic hormonal rhythm.

Once synthesized and exported from the pituitary gland, GH signals the liver and additional tissues to synthesize and secrete insulin-like growth factor-1 (IGF-1), the paramount orchestrator of tissue building, restoration processes, and cellular multiplication. The coordinated function of GH and IGF-1 constitutes a foundational regulatory system for metabolic equilibrium, lipid catabolism, and the biosynthesis of contractile proteins. In particular, GH exerts measurable effects on adipose tissue lipolysis—affecting both visceral and subcutaneous compartments—while concurrently safeguarding the integrity of skeletal muscle mass.

A principle advantage conferred by the DAC alteration lies in its formation of a covalent linkage with albumin molecules abundant in serum. Such bonding dramatically extends the peptide's circulation time, facilitating continued engagement of target receptors and propagation of the GH secretion signal. As a result, CJC-1295 with DAC maintains therapeutic activity across many days to weeks following injection—a substantial temporal advantage over non-DAC variants like standard CJC-1295 or unmodified GHRH(1-29).

At the subcellular level, CJC-1295 interaction with the GHRH receptor apparently initiates the cyclic AMP (cAMP) cascade, mediated by the activation of adenylate cyclase. Subsequent activation of protein kinase A (PKA) follows, instigating phosphorylation events in regulatory transcription factors and augmenting the transcription of GH-related genetic sequences within somatotropic pituitary cells. The prolonged persistence of the albumin-bound peptide maintains continuous activation through this pathway, generating cumulative increases in GH secretion and corresponding rises in IGF-1 compared to rapidly-degraded peptide alternatives.

Overall, CJC-1295 with DAC serves as a robust investigative platform for elucidating protracted endocrine stimulation phenomena, deciphering GH/IGF-1 regulatory axes, and characterizing metabolic manifestations of sustained GH secretion rhythmicity.

Structural and Chemical Characteristics

Chemical Properties

Appearance: White crystalline powder (lyophilized form)

Molecular Formula: C₁₆₅H₂₇₁N₄₇O₄₆

Molecular Weight: ~3647.9 g/mol

Sequence: DAC-modified variant of GHRH(1–29)

Purity Standard: ≥ 98% as confirmed by analytical certification

CJC-1295 with DAC: Experimental Protocol Considerations

Environmental Conditions and Long-Term Preservation

The compound is supplied in a sterile, lyophilized powder format optimized for research applications. Maintaining temperatures of –20°C in the freeze-dried state provides the best assurance for preservation of molecular architecture and biological function. Once reconstitution takes place, the preparation must be protected from contamination using aseptic technique and held within a 2–8°C range for near-term investigations. Such conditions protect against chemical degradation pathways and reduce the probability of microbial contamination affecting experimental integrity.

Impact on GH Secretion Patterns

Clinical observations and preclinical model systems demonstrate that a solitary dose of CJC-1295 with DAC results in sustained elevation of plasma GH and IGF-1 extending approximately one week. This protracted endocrine profile offers striking contrast to the transient responses of native GHRH(1-29) or non-DAC peptide formulations. Measured data reveal approximate 2–3-fold expansion of IGF-1 concentrations with maintained pulsatile GH patterns, confirming enhanced receptor-mediated biological activity and sustained peptide presence in blood.

CJC-1295 with DAC and Metabolic State Modulation

Experimental observations propose that CJC-1295 with DAC generates substantial metabolic effects attributable to elevated circulating GH and IGF-1 availability. Preclinical study findings report elevated rates of lipid hydrolysis, augmented oxidative fat metabolism, and sustained preservation of muscular tissue, all concordant with known GH roles in energy mobilization and lean tissue preservation. Investigation has encompassed the peptide's contribution to protein assembly mechanisms, expedited tissue regeneration, and systemic energy expenditure regulation, establishing utility as an instrument for dissecting GH-dependent metabolic regulation.

CJC-1295 with DAC Pharmacokinetic Profile: Circulation Duration

Differentiated from shorter-acting GHRH receptor agonists, the DAC component of CJC-1295 creates covalent linkages with albumin in circulation, substantially reducing both renal excretion and enzymatic inactivation. The strong association between peptide and albumin radically prolongs the molecule's permanence within the bloodstream, enabling continuous activation of biological signaling and extended endocrine responsiveness. Pharmacokinetic modeling indicates an elimination half-life spanning approximately 5.8 to 8.1 days, substantially exceeding the minutes-to-hours clearance of non-albumin-binding congeners, thereby permitting reduced dosing intervals in experimental designs.

Authorship and Expert Attribution

Document Compilation and Editorial Oversight

This literature review has been meticulously compiled, critiqued, and organized by Dr. Stuart L. Teichman, M.D. An internationally recognized endocrinologist and clinical research investigator, Dr. Teichman has made transformative contributions to understanding extended-duration GHRH analogs, particularly CJC-1295. His definitive investigations have delineated the pharmacological characteristics, safety considerations, and therapeutic prospects of GHRH-class molecules, highlighting their remarkable potential to generate sustained GH and IGF-1 elevation. Dr. Teichman's scholarly efforts have substantially transformed the discipline of peptide endocrinology and rational design of long-acting hormonal therapeutics.

Professional and Academic Contributions

Dr. Stuart L. Teichman's research interests span growth hormone secretagogues, GHRH peptide analogs, and peptide-mediated regulation of endocrine function. Through ongoing collaborations with accomplished researchers such as A. Neale, B. Lawrence, and C. Gagnon, Dr. Teichman has produced comprehensive scientific literature illuminating the mechanistic basis of prolonged-acting GHRH medications, their regulatory influence on the GH/IGF-1 biosystem, and their broad-spectrum metabolic ramifications. His aggregated research contributions constitute an authoritative scientific foundation for the creation of modern peptide-based pharmaceutical agents optimized for hormonal regulation and metabolic optimization.

This acknowledgment exists solely for proper scientific attribution and should not be interpreted as an endorsement message or marketing communication. Montreal Peptides Canada maintains no institutional connection, sponsoring relationship, or professional collaboration with Dr. Teichman or the referenced collaborators.

Primary Scientific Literature Citations

Teichman SL, Neale A, Lawrence B, Gagnon C, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/

Broglio F, et al. Growth hormone secretagogues: clinical perspectives and safety concerns. Growth Horm IGF Res. 2009;19(1):1-9. https://pubmed.ncbi.nlm.nih.gov/19054601/

Ghigo E, et al. Growth hormone secretagogues: physiology and clinical applications. Endocr Rev. 2005;26(3):345-376. https://pubmed.ncbi.nlm.nih.gov/15814849/

Anderson-Baucum EK, et al. GH/IGF-1 axis and metabolic regulation. Mol Cell Endocrinol. 2018;469:1-14. https://pubmed.ncbi.nlm.nih.gov/29288913/

Wu Z, et al. Growth hormone and IGF-1 signaling in muscle metabolism. Front Endocrinol (Lausanne). 2020;11:607. https://pubmed.ncbi.nlm.nih.gov/33281526/

Ranke MB, Wit JM. Growth hormone-past, present and future. Nat Rev Endocrinol. 2018;14(5):285-300. https://pubmed.ncbi.nlm.nih.gov/29479014/

Strasburger CJ, et al. GH and IGF-1 in clinical practice: new insights. Eur J Endocrinol. 2021;185(6):R123-R136. https://pubmed.ncbi.nlm.nih.gov/34870144/

Smith TR, et al. The role of GH and IGF-1 in tissue repair and regeneration. Exp Gerontol. 2015;68:46-52. https://pubmed.ncbi.nlm.nih.gov/25987250/